Medium-Chain Triglycerides for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Medium-Chain Triglycerides for Health & Longevity

Created on 08/26/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

The liver turns these rapidly absorbed oils into ketone fuels even with carbohydrate present. The most consistent finding is a small reduction in body weight and fat when they replace other fats. Thinking gains in some older adults with memory problems are modest and mixed. Cramping, diarrhea, and nausea are the main drawback. They are not a general longevity drug. (Full Review)

Protocol

Typical daily amount
18–30 g/day
Weight and cognition protocols; 6 g/day for frailty; up to 40 g/day tricaprilin in Alzheimer trials
Titration
About 5 g (1 teaspoon)
Typical protocols increase every few days to limit diarrhea
Split versus single dose
Split doses with food
Split doses with food reduce gut symptoms; a single bolus produces a higher ketone peak
Time to effect
Modest Body-Weight and Fat-Mass Reduction
4–16 weeks
Weight and waist changes when replacing, not adding, other dietary fats
Cognitive Performance in Mild Cognitive Impairment and Alzheimer Disease
45–180 days
Cognitive trial durations
Lower Subsequent Energy Intake
Acute
Later unrestricted intake after MCT versus long-chain fat

Benefits

Contraindications
  • MCAD deficiency (ACADM-related medium-chain acyl-CoA dehydrogenase deficiency)
  • Severe hepatic cirrhosis or portal hypertension (Child-Pugh Class C; portacaval shunt)
  • Pregnancy at supplemental (not culinary) doses
  • Active inflammatory bowel disease, recent gastrointestinal bleed, or uncontrolled severe reflux
  • Type 1 diabetes with prior diabetic ketoacidosis, unless ketones and insulin are closely tracked
    •
Key Interactions
  • SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin)
  • Insulin and sulfonylureas (glipizide, glyburide)
  • Orlistat
  • Exogenous ketone salts or esters
  • Coconut oil and other C12-rich fats
  • Leucine and vitamin D
    •

Risk & Side Effects

  • High: Gastrointestinal Intolerance; Fasting Triglyceride Increase
    •
  • Medium: LDL Cholesterol Increase Versus Unsaturated Oils
    •
  • Low: Hepatic Strain in Advanced Liver Disease; Displacement of Essential Fatty Acids
    •
  • Speculative: Ketoacidosis When Combined With Sodium-Glucose Cotransporter-2 Inhibitors or Type 1 Diabetes
    •

Monitoring

Marker Target Why
ApoB 40–80 mg/dL Particle-number risk if MCT replaces unsaturated fat
LDL cholesterol 50–100 mg/dL Same lipid substitution question
Fasting triglycerides 50–100 mg/dL MCT meta-analysis raised triglycerides slightly
HbA1c 4.8–5.3% Glucose handling if diabetes drugs are in use
Blood BHB Change from own baseline; many ketogenic protocols aim 0.3–1.0 mmol/L Confirms a ketone rise from C8 dose
ALT/AST Stay near personal baseline; conventional ALT often <30–40 U/L Hepatic handling in high-dose or liver-disease settings

Cadence: Baseline before daily use; 4–8 weeks after a stable dose, then every 6–12 months; earlier if severe diarrhea, triglycerides rise, or glucose-lowering drugs are in use

Qualitative Assessment

  • Gut comfort within the first 2 weeks
  • Waist circumference and scale weight at 4–8 weeks if body composition is the goal
  • Subjective mental clarity 60–120 minutes after a C8 dose
  • Gait speed or chair-stand versus the individual’s baseline (frailty)
  • Montreal Cognitive Assessment or a computerized battery versus baseline (memory clinics)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.